Seeking Alpha
16 Jan 2026, 10:13 UTC · 35w ago
Verdict
Headline takes no side. We score NRIX +0.90 across three claims — strongly bullish.
+0.90strongly bullish
More positive than 95% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
NX-5948 demonstrated an 83% response rate and 22.1 months of progression-free survival in Phase 1 CLL trials.
More positive than 98% of claims this week
Nurix Therapeutics will move NX-5948 directly into Phase 3 trials.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 91% of claims this week
The company holds $680M in cash, providing a runway through 2027-2028.
So whatSubstantial liquidity reduces the immediate need for capital raises, thereby minimizing shareholder dilution.
More positive than 76% of claims this week
Which stocks this story touches
More positive than 95% of ticker scores this week
Strong Phase 1 efficacy data and a healthy cash position supporting R&D without immediate dilution risk.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
The Motley Fool
1d ago
+35.2%
Price agrees with the score
$25.50 vs $18.86 close before publication (Jan 15) · not market-adjusted
NRIX chart →
